Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation
- 16 December 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 288-294
- https://doi.org/10.1016/j.jcf.2020.11.020
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation
This publication has 18 references indexed in Scilit:
- The Tinnitus Functional IndexEar & Hearing, 2012
- Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissionsInternational Journal of Audiology, 2010
- No hearing loss after repeated courses of tobramycin in cystic fibrosis patientsActa Oto-Laryngologica, 2010
- Cystic Fibrosis Pulmonary GuidelinesAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis PatientsAntimicrobial Agents and Chemotherapy, 2006
- Effectiveness of Primary Care–Based Vestibular Rehabilitation for Chronic DizzinessAnnals of Internal Medicine, 2004
- Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside TherapyAntimicrobial Agents and Chemotherapy, 2001
- Aminoglycoside-induced ototoxicityToxicology Letters, 1990
- Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosisAntimicrobial Agents and Chemotherapy, 1987
- Renal and Auditory Toxicity of High-Dose, Prolonged Therapy with Gentamicin and Tobramycin in Pseudomonas EndocarditisThe Journal of Infectious Diseases, 1984